Evidence to support peripheral and central IL-6 signaling targets to treat depression

"Evidence to support peripheral and central IL-6 signaling targets to treat depression." Expert Opinion on Investigational Drugs, 24(7), pp. 991–992

Declaration of interest

TM Fonseka is a recipient of a Canadian Institutes of Health Research (CIHR) 2012 Frederick Banting and Charles Best Masters Award. RS McIntyre has received grant/research support from: Stanley Medical Research Institute, National Alliance for Research on Schizophrenia and Depression (NARSAD), and National Institutes of Mental Health. SH Kennedy has received grant/research support from Bristol Myers Squibb, Canadian Institutes of Health Research, Clera Inc., Lundbeck A/S, the Ontario Brain Institute and St. Jude Medical. RS McIntyre has received research grants from Eli Lilly and Co., Janssen-Ortho, Shire, AstraZeneca, Pfizer, Inc., and Lundbeck A/S. He has also served on advisory boards and/or speakers’ bureaus, and/or participated in CME activities for: AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho, Eli Lilly and Co., Organon, Lundbeck A/S, Pfizer, Inc., Shire, Merck & Co., I3CME, Physicians’ Postgraduate Press, CME Outfitters, and Optum Health. JK Soczynska has received fellowship funding from Eli Lilly Canada. SH Kennedy has received speaking fees from and/or is a member of an advisory board for: Actavis, Bristol-Myers Squibb, Eli Lilly and Co., Janssen Pharmaceuticals, Lundbeck A/S, Lundbeck Institute, Naurex, Inc., Pfizer, Inc. and Servier and St Jude Medical.